EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 128 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR How will new cancer medicines be approved in the future? December 2, 2021 A Cancer Revolution comes to Manchester: Patrick’s review November 24, 2021 Mapping Cancer Genomic Evolution Offers Insights into Tumor Development March 6, 2020 FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer February 13, 2025 Load more HOT NEWS Foodie Fridays: It’s Cucumber Season! Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment... From Awareness to Action: Putting Cancer Disparities in the Rearview Mirror EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab
